Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Novan stock in Canada | $7.805

Own Novan shares in just a few minutes.

Novan, Inc
-$0.21 (-2.44%)

Novan is a biotechnology business based in the US. Novan stocks (NOVN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $10.68 – a decrease of 6.53% over the previous week. Novan employs 23 staff and has a trailing 12-month revenue of around $4.5 million.

How to buy Novan stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: NOVN in this case.
  5. Research Novan stocks. The platform should provide the latest information available.
  6. Buy your Novan stocks. It's that simple.

How has Coronavirus impacted Novan's stock price?

Since the stock market crash in March caused by coronavirus, Novan's stock price has had significant positive movement.

Its last market close was $7.805, which is 92.94% up on its pre-crash value of $0.5511 and 3,530.23% up on the lowest point reached during the March crash when the stocks fell as low as $0.215.

If you had bought $1,000 worth of Novan stocks at the start of February 2020, those stocks would have been worth $1,246.74 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $15,656.99.

Novan stock price

Use our graph to track the performance of NOVN stocks over time.

Novan stocks at a glance

Information last updated 2021-07-22.
Latest market close$7.805
52-week range$3.67 - $25.9
50-day moving average $10.0488
200-day moving average $12.9313
Wall St. target price$47
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.959

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Novan stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Novan price performance over time

Historical closes compared with the last close of $7.805

1 month (2021-06-25) -26.92%
3 months (2021-04-26) 473.90%

Novan financials

Revenue TTM USD$4.5 million
Gross profit TTM USD$-3,907,000
Return on assets TTM -41.53%
Return on equity TTM 0%
Profit margin 0%
Book value $0.056
Market capitalisation USD$168.7 million

TTM: trailing 12 months

How to short and sell Novan stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "NOVN.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 900,681 Novan stocks held short by investors – that's known as Novan's "short interest". This figure is 25.6% down from 1.2 million last month.

There are a few different ways that this level of interest in shorting Novan stocks can be evaluated.

Novan's "short interest ratio" (SIR)

Novan's "short interest ratio" (SIR) is the quantity of Novan stocks currently shorted divided by the average quantity of Novan stocks traded daily (recently around 10.0 million). Novan's SIR currently stands at 0.09. In other words for every 100,000 Novan stocks traded daily on the market, roughly 90 stocks are currently held short.

However Novan's short interest can also be evaluated against the total number of Novan stocks, or, against the total number of tradable Novan stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novan's short interest could be expressed as 0.05% of the outstanding stocks (for every 100,000 Novan stocks in existence, roughly 50 stocks are currently held short) or 0.0622% of the tradable stocks (for every 100,000 tradable Novan stocks, roughly 62 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Novan.

Find out more about how you can short Novan stock.

Novan stock dividends

We're not expecting Novan to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have Novan stocks ever split?

Novan stocks were split on a 1:10 basis on 26 May 2021. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novan stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for Novan stocks which in turn could have impacted Novan's stock price.

Novan stock price volatility

Over the last 12 months, Novan's stocks have ranged in value from as little as $3.67 up to $25.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novan's is -0.0349. This would suggest that Novan's stocks have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Novan has bucked the trend.

Novan overview

Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is based in Durham, North Carolina.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site